Abstract
Introduction Blood-based Alzheimer’s disease (AD) biomarkers provide opportunities for community studies and across ethnic groups. We investigated blood biomarker concentrations in the Washington Heights, Inwood, Columbia Aging Project (WHICAP), a multi-ethnic community study of aging and dementia.
Methods We measured plasma Aβ40, Aβ42,T-tau, P-tau181 and P-tau217, and neurofilament light chain (NfL) in 113 autopsied participants, (29% with high AD neuropathological changes) and in 300 clinically evaluated individuals (42% with clinical AD). Receiver operating characteristics were used to evaluate each biomarker. We also investigated biomarkers as predictors of incident clinical AD.
Results P-tau181, P-tau217 and NfL concentrations were elevated in pathologically and clinically diagnosed AD. Decreased Aβ42/Aβ40 ratio and increased P-tau217 and P-tau181 were associated with subsequent AD diagnosis.
Discussion Blood-based AD biomarker concentrations are associated with pathological and clinical diagnoses and can predict future development of clinical AD, providing evidence that they can be incorporated into multi-ethnic, community-based studies.
Competing Interest Statement
The following authors have no conflicts of interest to report: Adam Brickman, Jennifer J.Manly, Lawrence S. Honig, Danurys Sanchez, Dolly Reyes-Dumeyer, Rafael A. Lantigua, Patrick J. Lao, Yaakov Stern, Jean Paul Vonsattel, Andrew F. Teich and Richard Mayeux. David Charles Airey, Nicholas Kyle Proctor and Jeffrey L. Dage are employees and stock holders of Eli Lilly and Company.
Funding Statement
Data collection and sharing for this project was supported by the Washington Heights-Inwood Columbia Aging Project (WHICAP; P01AG07232, RF1AG054023, R01AG037212, R56AG034189, R01AG034189, R01AG054520) funded by the National Institute on Aging (NIA). This manuscript has been reviewed by WHICAP investigators for scientific content and consistency of data interpretation with previous WHICAP Study publications. We acknowledge the WHICAP study participants and the WHICAP research and support staff for their contributions to this study. Florbetaben was provided to the study by Life Molecular Imaging (formally Piramal Imaging) under an Investigator Initiated Study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Columbia University Medical Center IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The following authors have no conflicts of interest to report: Adam Brickman, Jennifer J.Manly, Lawrence S. Honig, Danurys Sanchez, Dolly Reyes-Dumeyer, Rafael A. Lantigua, Patrick J. Lao, Yaakov Stern, Jean Paul Vonsattel, Andrew F. Teich and Richard Mayeux. David Charles Airey, Nicholas Kyle Proctor and Jeffrey L. Dage are employees and stock holders of Eli Lilly and Company.
Data Availability
WHICAP data are available through written request to the corresponding author.
